News  >  Breaking News  >  CFDA Approves Pfizer Oral Arthritis Treatment for China Use

CFDA Approves Pfizer Oral Arthritis Treatment for China Use

By Editing NAI
03/16/2017 5:54 p.m.

Pfizer has received permission from the CFDA to market an oral treatment for rheumatoid arthritis in China. Xeljanz® (tofacitinib citrate), a Janus kinase inhibitor, is indicated for adult patients with moderately to severely active rheumatoid arthritis whose disease does not respond to methotrexate (MTX). Pfizer says Xeljanz, which was granted marketing approval in the US in 2012, is the first oral JAK inhibitor approved for RA patients in China.

Source: ChinaBio Today


No Comments

Please to leave a comment.

Related News

Schlumberger says bought stake in rig firm Borr Drilling
03/29/2017 1:31 a.m.
Shanghai, Beijing listed among top 20 global financial hubs
03/29/2017 12:53 a.m.
Alibaba Sells More Momo Inc Shares, Reducing Its Holding in Mobile Social Networking Firm to 14%
03/28/2017 10:59 p.m.
Oil rises on Libyan supply disruptions, likely OPEC output cut extension
03/28/2017 10:35 p.m.
China Surpasses Singapore as Malaysia’s Largest Property Investor
03/28/2017 9:33 p.m.

Upcoming Events More


GCFF Vancouver Conference 2017 - Discovering Alternative Investments in Innovation

Over the years, investors have seen how exciting opportunities in innovation have matured into solid investments. Advances in AI, Big Data, Clean Technology and Health Care have all led ... Event Info